How the FDA Regulates Peptides
The FDA regulates peptide therapies through the same framework it uses for all drugs and biological products. When a pharmaceutical company develops a new peptide drug, it must go through the full drug approval process - preclinical testing, Phase 1-3 clinical trials, and New Drug Application (NDA) or Biologics License Application (BLA) review. This process typically takes 10-15 years and costs hundreds of millions of dollars. Peptides that complete this process receive FDA approval for specific indications with defined dosing, contraindications, and labeling.
Several peptide-based finished products have received full FDA approval. The semaglutide finished products Ozempic and Wegovy are approved for type 2 diabetes and for chronic weight management, respectively. The tirzepatide finished products Mounjaro and Zepbound are approved for type 2 diabetes and for chronic weight management, respectively. These approved finished products have the most comprehensive safety and efficacy data available.
Many peptide-based preparations are not commercially available as FDA-approved finished products - not because they are unsafe, but because the approval process is designed for pharmaceutical companies seeking commercial exclusivity. Naturally occurring peptides and established cofactors (the kind used in compounded NAD+ and glutathione preparations) are often not commercially viable for the approval process. These preparations are available through licensed compounding pharmacies under a separate regulatory framework, on individual physician prescription.
Compounding Pharmacy Regulations
Compounding pharmacies operate under a specific regulatory framework that allows them to prepare customized medications, including peptides, under the supervision of a pharmacist. There are two primary regulatory categories for compounding pharmacies under the Federal Food, Drug, and Cosmetic Act.
Section 503A pharmacies prepare compounded medications in response to individual patient prescriptions from licensed physicians. These pharmacies are primarily regulated by state boards of pharmacy and must meet state-specific quality standards. They compound medications on a patient-by-patient basis and cannot distribute products across state lines without state-level agreements.
Section 503B pharmacies - also called outsourcing facilities - are registered with and inspected by the FDA. They follow current Good Manufacturing Practices (cGMP), conduct sterility and potency testing, and can distribute compounded products in larger quantities. These facilities undergo regular FDA inspections and are held to higher manufacturing standards than 503A pharmacies. GetPepWell partners with pharmacies that meet or exceed these regulatory standards to ensure our patients receive safe, accurately dosed medications.
Understanding Peptide Regulatory Categories
Peptide-based preparations fall into several regulatory categories that patients should understand. FDA-approved finished products have completed the full approval process and have defined labeling, approved indications, and post-market surveillance. These represent the highest level of regulatory oversight and evidence support.
Compounded preparations are prepared by licensed pharmacies using bulk pharmaceutical ingredients. When a molecule is available as an FDA-approved finished product (semaglutide and tirzepatide are examples), compounding pharmacies can prepare compounded versions under certain conditions - typically when there are documented shortages or when the compounded version offers a clinically meaningful difference (such as a different dosage form or strength). The regulatory landscape around compounding of commercially available products is complex and evolving.
Some molecules exist in a category where they have a well-characterized biological role but no FDA-approved finished-product equivalent for any specific indication. NAD+ and glutathione, both naturally occurring intracellular molecules used as compounded preparations in this catalog, fall into this category. These compounded preparations are available through licensed compounding pharmacies and can be prescribed by physicians exercising their clinical judgment, but patients should understand that the evidence base differs from that of an FDA-approved finished product.
Recent Regulatory Developments
The regulatory landscape for peptides has been evolving significantly. The FDA has been reviewing its approach to compounded peptides, particularly regarding which bulk drug substances can be used in compounding. The agency maintains a list of substances that can be used in compounding (the "bulks" list) and has been evaluating specific peptides for inclusion or exclusion from this list.
These regulatory changes affect the availability of certain compounded peptides. When the FDA determines that a peptide should not be on the bulks list, compounding pharmacies may no longer be able to prepare it. Conversely, inclusion on the bulks list confirms that a substance can be compounded under the appropriate regulatory framework. Patients should be aware that the availability of specific compounded peptides may change as regulatory reviews are completed.
GetPepWell stays current with all regulatory developments and adjusts our product offerings accordingly. If a regulatory change affects a peptide you are currently using, your physician will proactively contact you to discuss alternative treatment options. We only offer peptides that are legally available through properly licensed compounding pharmacies in full compliance with current federal and state regulations.
What This Means for Patients
Understanding the regulatory framework helps patients make informed decisions about peptide therapy. When your physician recommends a specific peptide, ask about its regulatory status - is it FDA-approved for your indication, FDA-approved for a different indication (off-label use), or a compounded product? Each category carries different levels of evidence and oversight, and understanding where your treatment falls helps you participate meaningfully in treatment decisions.
Patients should know their rights and protections. You have the right to know which pharmacy is preparing your medication, to receive information about the peptide's regulatory status, to understand the evidence supporting its use, and to be informed of any regulatory changes that affect your treatment. A responsible provider like GetPepWell proactively shares this information without patients having to request it.
The most important protection patients have is working with a licensed physician who prescribes based on clinical evidence and medical judgment, and a licensed pharmacy that compounds under regulatory oversight. This combination of medical expertise and pharmaceutical quality control provides a safety framework that unregulated peptide sales simply cannot match. If a provider or supplier cannot clearly explain the regulatory basis for the products they offer, that is a significant red flag.
Avoiding Unregulated Products
The growth of interest in peptide-based medicine has led to a proliferation of unregulated products sold online by suppliers that bypass any prescription requirement. These products are not manufactured under pharmaceutical standards, are not tested for human safety, and are not subject to any regulatory oversight. Independent testing of grey-market supply has repeatedly found contamination, incorrect potency, and even entirely wrong compounds.
Red flags that indicate an unregulated source include: no prescription required, no pharmacy license displayed, prices significantly below market rates, no physician consultation offered, products shipped from overseas without proper import controls, and payment accepted only via cryptocurrency or wire transfer.
Legitimate peptide-based care always involves a licensed physician consultation, a valid prescription, and dispensing from a licensed pharmacy. At GetPepWell, every step of the process - from medical evaluation to prescription to pharmacy fulfillment - occurs within the regulated healthcare system. This is not a marketing distinction; it is a fundamental safety requirement. Patients who obtain compounded preparations outside this framework accept significant and unnecessary health risks.